August 31, 2017
A California federal judge on Thursday sent AbbVie Inc.'s suit seeking to nix Novartis' hepatitis C patents to arbitration, finding that while a licensing agreement between the companies was so grammatically unclear he consulted his Chicago Manual of Style, the ambiguity triggers a presumption in favor of the Federal Arbitration Act.
August 17, 2017
A California federal judge said Thursday he was likely to send AbbVie Inc.'s suit seeking to nix Novartis' hepatitis C patents to arbitration, saying a licensing agreement between the companies was grammatically vague about where invalidity arguments should be decided, and so he would follow a "general rule" of favoring arbitration.
April 03, 2017
AbbVie Inc. is looking to invalidate a suite of Novartis patents, arguing Friday in California that its Swiss rival is collecting licensing fees on the genetic makeup of the Hepatitis C virus, despite the U.S. Supreme Court's Alice ruling expressly stating nature itself can't be patented.